Clinical Trial

Study on Impact of Maximal Strength Training in Patients With COPD

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 23, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
In the context of pulmonary rehabilitation of COPD patients, recent guidelines and metanalysis describe that Resistance Training (RT) can be successfully performed alone or in conjunction with Endurance Training (ET) without evidence of adverse events. Maximal Strength Training (MST) is a kind of RT typically performed at \~85-90% of 1RM with maximal velocity to be developed in the concentric phase. Recent literature indicates a significant amelioration on the Rate of Force Development (RFD) after MST in healthy subjects, post-menopausal woman and older populations. When comparing to the conventional ET, MST generates a little change in muscle mass (no hypertrophy), but a much greater improvement in the RFD. It has been described that neural adjustments play a major role in the MST-induced adaptations. MST is also well documented to improve aerobic endurance by improving walking work efficiency. Only a small cohort study of COPD patients was conducted, describing that MST can meaningfully improve strength and RFD, with an increase of around 32% for mechanical efficiency and a decrease of the perceived effort during submaximal job. This improvement could determine best performances in daily activities and a best quality of life. The main aims of this physiological pilot randomized controlled trail will be to evaluate feasibility and efficacy of the MST compared to standard ET on strength, effort tolerance, fatigue, economy of walking, dyspnea and risk of falls in a populations of COPD patients, in a short and middle term (6 months).
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2019-01-07; most recent amendment 2026-02-20.
Status change: Not Yet Recruiting → Recruiting 2019-11-12
Trial Details
NCT Number NCT03799354
Lead Sponsor Istituti Clinici Scientifici Maugeri SpA
Collaborators: Universita di Verona
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 20 participants
Start Date 2019-09-18
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-23